Feed VTRS
VT

Viatris

VTRS · NASDAQ

$16.51 -0.06% (-$0.01)
1M +2.93%
Market Cap $19.1B
P/E Ratio -
Div. Yield 2.93%
ROE 2.79%

Bulios Fair Price

$15.36

7.0% downside

Trenutna cena

$16.51

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica VTRS trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
7/9
Valuation
86 /100
Cheap
P/S 1.29x
P/B 1.34x
P/FCF 10.18x
Growth
0 /100
Declining
FCF growth 8.27%
Book val. growth 11.29%
Rev. growth 4.20%
Profitability
37 /100
Moderate
Net margin 2.79%
Op. margin 0.59%
FCF margin 12.71%
Quality
5 /100
Poor
ROE 2.79%
ROA 1.17%
Asset turnover 0.42x
Debt
32 /100
High
Current ratio 1.58x
Int. coverage -0.18x
Net debt/EBITDA 4.82x
Stability
56 /100
Moderate
Rev. volatility 1.10%
EPS volatility 599.63%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o VTRS
Online

O podjetju

Viatris Inc. is a pharmaceutical company formed through the merger of two significant pharmaceutical firms. The company specializes in research, development, and manufacturing of prescription medicines, generic drugs, and biosimilars. Viatris offers a broad range of medications for various diseases, from common ailments to serious health conditions. The company is active in the global pharmaceutical market, providing treatment for millions of patients worldwide. Viatris focuses on improving accessibility and affordability of medicines and providing quality alternative treatment options. The company also invests in research for new drugs and treatment approaches to better address patients' healthcare needs. Viatris Inc. (VTRS) shares are an interesting choice for investors who follow the pharmaceutical sector and seek investment opportunities in a global pharmaceutical company with an extensive portfolio of medicines and research activities.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Scott Andrew Smith

Employees

30,000

Headquarters

Canonsburg

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

54d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.